Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Shanghai Junshi Biosciences CO Ltd (OP:SHJBF)

3.080 +0.090 (+3.01%)
Streaming Delayed Price Updated: 12:19 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Shanghai Junshi Biosciences CO Ltd

News headline image
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗
Jiangsu Hengrui Pharma out-licensed global rights for its next-gen PARP1 inhibitor to Germany’s Merck KGaA for a $170 million upfront payment and up to $1.5 billion in milestones. Merck will have... 
Via Talk Markets
News headline image
Week In Review: Apollomics Merges With SPAC To Support Candidates Targeting Difficult-To-Treat Cancers ↗
Apollomics, Inc., a US-China biopharma, merged with a SPAC to list on the Nasdaq exchange. At the merger price of $10/share, Apollomics had a market cap of about $900 million, but the shares have... 
Via Talk Markets
News headline image
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
News headline image
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug ↗
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.